Furthermore, the synergism of chidamide and decitabine as two kinds of epigenetic regulatory drugs was also identified, and more importantly, we observed that decitabine could enhance the HDAC inhibitory activity of chidamide in Hodgkin lymphoma cell lines. The gene discussed is HDAC9; the disease is Hodgkins lymphoma.